We are live on
!
Find out more
DGM
Darwin Global Management Portfolio holdings
AUM
$3.77B
1-Year Est. Return
307.72%
This Fund
S&P 500
This Quarter
Est. Return
-3.85%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$511M
AUM Growth
+$152M
(+42%)
Cap. Flow
+$178M
Cap. Flow
% of AUM
34.79%
Top 10 Holdings %
Top 10 Hldgs %
99.69%
Holding
15
New
3
Increased
6
Reduced
3
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$93.4M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$73.2M |
| 3 |
Fate Therapeutics
FATE
|
+$40M |
| 4 |
Relay Therapeutics
RLAY
|
+$34M |
| 5 |
Arvinas
ARVN
|
+$8.06M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$57.3M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$19.6M |
| 3 |
C4 Therapeutics
CCCC
|
+$3.52M |
| 4 |
Immunovant
IMVT
|
+$3.52M |
| 5 |
Stoke Therapeutics
STOK
|
+$372K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
1
DELISTED
Acceleron Pharma
XLRN
| $204M | 39.97% |
1,505,012
+566,522
| +60% | +$73.2M |
|
|
2
BridgeBio Pharma
BBIO
$15.9B
| $129M | 25.21% |
2,090,149
+1,427,191
| +215% | +$93.4M |
|
|
3
Fate Therapeutics
FATE
$324M
| $113M | 22.12% |
1,370,133
+417,286
| +44% | +$40M |
|
|
4
Relay Therapeutics
RLAY
$4.34B
| $27.1M | 5.3% |
+782,471
| New | +$34M |
|
|
5
Arvinas
ARVN
$517M
| $9.29M | 1.82% |
140,511
+105,311
| +299% | +$8.06M |
|
6
MacroGenics
MGNX
$285M
| $9.12M | 1.78% |
+286,195
| New | +$6.95M |
|
|
GBIO
7
DELISTED
Generation Bio
GBIO
| $6.24M | 1.22% |
21,936
+2,217
| +11% | +$710K |
|
8
Keros Therapeutics
KROS
$211M
| $5.35M | 1.05% |
+86,887
| New | +$5.5M |
|
|
9
C4 Therapeutics
CCCC
$408M
| $5.18M | 1.01% |
140,034
-88,561
| -39% | -$3.52M |
|
|
10
Immunovant
IMVT
$8.27B
| $1.06M | 0.21% |
65,849
-133,420
| -67% | -$3.52M |
|
|
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $998K | 0.2% |
49,709
+13,175
| +36% | +$385K |
|
12
Fulcrum Therapeutics
FULC
$243M
| $587K | 0.11% |
49,868
-11,445
| -19% | -$142K |
|
|
13
Sarepta Therapeutics
SRPT
$1.82B
| – | – |
-114,900
| Closed | -$19.6M |
|
|
14
Stoke Therapeutics
STOK
$1.81B
| – | – |
-6,000
| Closed | -$372K |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-260,876
| Closed | -$57.3M |
|
Similar funds
VVP
ABC
SCA
ACH
GL
VA
GCC
SB
Darwin Global Management's Q1 2021 Portfolio in Review
As of Q1 2021, Darwin Global Management held 15 positions worth $511M, up 42% from $358M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Darwin Global Management deployed $178M of net new capital in Q1 2021, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was Relay Therapeutics: 782,471 shares worth $27.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was C4 Therapeutics, an estimated $3.52M trimmed.
- Darwin Global Management's largest Q1 2021 buy was Relay Therapeutics: 782,471 shares worth $27.1M.
- Darwin Global Management added most to BridgeBio Pharma in Q1 2021, an estimated $93.4M increase.
- Darwin Global Management's biggest Q1 2021 reduction was C4 Therapeutics, cutting an estimated $3.52M.
- Darwin Global Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $57.3M.
- Darwin Global Management's ten largest holdings make up 100% of its $511M portfolio in Q1 2021.
- Darwin Global Management opened 3 new positions and closed 3 in Q1 2021.
- Darwin Global Management's portfolio value rose 42% quarter-over-quarter to $511M.
Based on Darwin Global Management's 13F filing for Q1 2021, filed 17 May 2021.